Last 1,080 GBp
Change Today +5.00 / 0.47%
Volume 1.6M
SN/ On Other Exchanges
Symbol
Exchange
London
New York
OTC US
Frankfurt
Frankfurt
As of 11:35 AM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

smith & nephew plc (SN/) Snapshot

Open
1,065 GBp
Previous Close
1,075 GBp
Day High
1,086 GBp
Day Low
1,059 GBp
52 Week High
06/5/14 - 1,136 GBp
52 Week Low
10/9/13 - 737.50 GBp
Market Cap
9.6B
Average Volume 10 Days
1.8M
EPS TTM
0.58 GBp
Shares Outstanding
893.0M
EX-Date
10/23/14
P/E TM
30.0x
Dividend
0.30 GBp
Dividend Yield
1.71%
Current Stock Chart for SMITH & NEPHEW PLC (SN/)

Related News

No related news articles were found.

smith & nephew plc (SN/) Related Businessweek News

No Related Businessweek News Found

smith & nephew plc (SN/) Details

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The company’s Advanced Surgical Devices segment offers orthopaedic reconstruction implants for hip, knee, and shoulder joints; and ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. It also provides sports medicine products, which offer surgeons an array of instruments, technologies, and implants to perform minimally invasive surgery of the joints, including knee, hip, and shoulder repair; and trauma and extremities products consisting of internal and external devices and other products, including shoulder fixation and orthobiological materials used in the stabilization of fractures and deformity correction procedures. In addition, this segment provides arthroscopy enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, as well as offers radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissues to healthcare providers. The company’s Advanced Wound Management segment offers a range of initial wound bed preparation and full wound closure products. Its products are targeted at chronic wounds associated with the older population, such as pressure sores and venous leg ulcers; and products for the treatment of wounds, such as burns and invasive surgery. Smith & Nephew plc primarily serves medical and surgical treatments and service providers. The company was founded in 1856 and is headquartered in London, the United Kingdom.

14,000 Employees
Last Reported Date: 08/1/14
Founded in 1856

smith & nephew plc (SN/) Top Compensated Officers

Chief Executive Officer, Director, Chairman o...
Total Annual Compensation: $4.2M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: $2.0M
Compensation as of Fiscal Year 2013.

smith & nephew plc (SN/) Key Developments

Pamela Kirby Retires as Non-Executive Director of Smith & Nephew plc

Smith & Nephew plc confirmed that Pamela Kirby retired as a non-executive director of the company, as previously announced on 10 April 2014.

Smith & Nephew plc Declares Interim Dividend, Payable on November 11, 2014; Reports Unaudited Group Earnings Results for Second Quarter and Six Months Ended June 28, 2014; Reaffirms Earnings Guidance for the Year 2014

Smith & Nephew plc announced that the interim dividend of 2014 of 11.0 US Dollar cents per ordinary share was declared by the board on July 31, 2014. This dividend will be payable on November 11, 2014 to shareholders whose names appear on the register at the close of business on October 24, 2014. The sterling equivalent per ordinary share will be set following the record date. Shareholders may elect to receive their dividend in either Sterling or US Dollars and the last day for election will be 24 October 2014. The company reported unaudited group earnings results for second quarter and six months ended June 28, 2014. For the quarter, the company’s revenue was $1,147 million against $1,074 million a year ago. Operating profit was $134 million against $188 million a year ago. Profit before tax was $128 million against $188 million a year ago. Profit attributable was $89 million or 9.9 cents per diluted share against $129 million or 14.2 cents per diluted share a year ago. Net cash inflow from operating activities was $142 million against $155 million a year ago. Capital expenditure was $96 million against $86 million a year ago. Adjusted earnings per share were 20.4 cents compared to 18.0 cents last year. Adjusted profit attributable was $182 million against $163 million a year ago. For the six months, the company’s revenue was $2,220 million against $2,149 million a year ago. Operating profit was $363 million against $395 million a year ago. Profit before tax was $349 million against $392 million a year ago. Profit attributable was $239 million or 26.6 cents per diluted share against $272 million or 29.9 cents per diluted share a year ago. Net cash inflow from operating activities was $233 million against $347 million a year ago. Capital expenditure was $161 million against $141 million a year ago. Net debt was $1,911 million, up from $216 million at the end of First Quarter 2014, following the closing of the ArthroCare acquisition. Adjusted earnings per share were 38.1 cents compared to 36.5 cents last year. Adjusted profit attributable was $340 million against $330 million a year ago. The estimated tax rate for the full year is 28.0% on trading results. Previous guidance for the full year remains unchanged, except for the impact of the distribution hold on RENASYS in the U.S. This, together with other factors mentioned in the presentation, means that its Wound performance for the full year is expected to be below market.

Smith & Nephew Appoints KPMG LLP as Auditor

Smith & Nephew announced the appointment of KPMG LLP (KPMG) as its auditor for the year ending December 31, 2015, subject to approval by shareholders at the 2015 Annual General Meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SN/:LN 1,080.00 GBp +5.00

SN/ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr486.00 DKK +2.00
CR Bard Inc $146.98 USD -0.95
Getinge AB kr186.10 SEK -0.60
Olympus Corp ¥3,830 JPY -5.00
St Jude Medical Inc $62.19 USD -0.89
View Industry Companies
 

Industry Analysis

SN/

Industry Average

Valuation SN/ Industry Range
Price/Earnings 30.1x
Price/Sales 3.5x
Price/Book 3.8x
Price/Cash Flow 29.9x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SMITH & NEPHEW PLC, please visit www.smith-nephew.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.